Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 8, 2000, Pages 1015-1022

  Ang, Y S ^a   Mahmud, N ^a   White, B ^a   Byrne, M ^a   Kelly, A ^a   Lawler, M ^a   McDonald, G S A ^a   Smith, O P ^a   Keeling, P W N ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; HEPARIN; HYDROCORTISONE; OROSOMUCOID; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CROHN DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FECES; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; FEMALE; HEPARIN; HUMANS; HYDROCORTISONE; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; TREATMENT OUTCOME;

EID: 0033852957     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00802.x     Document Type: Article

References (34)

1. 1 Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; i: 1067-70.
2. 2 Meyers S, Sachar DB, Goldberg JD, et al. Corticotrophin versus hydrocortisone in the intravenous treatment of ulcerative colitis. Gastroenterology 1983; 85: 351-7.
3. 3 Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-13.
4. 4 Selby WS, Barr GD, Ireland A, et al. Olsalazine in active ulcerative colitis. Br Med J 1985; 291: 1373-5.
5. 5 Meyers S, Sachar DB, Present DH, et al. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomised, placebo-controlled, double-blind, dose-ranging clinical trial. Scand J Gastroenterol 1988; 23(Suppl. 148): 29-37.
6. 6 Rao SS, Dundas SAC, Holdsworth CD. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut 1989; 30: 675-9.
7. 7 Lam A, Borde IT, Inwood MJ, et al. Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology 1975; 68: 245-51.
8. 8 Lee JCL, Spittell JA, Sauer WG, et al. Hypercoagulability associated with chronic ulcerative colitis. Changes in blood coagulation factors. Gastroenterology 1968; 54: 76-85.
9. 9 Koenigs KP, McPhedan P, Spiro HM. Thrombosis in IBD. J Clin Gastroenterol 1987; 9: 627-31.
10. 10 Dillon AP, Anthony A, Sim R, et al. Mucosal capillary thrombi in rectal biopsy. Histopathology 1992; 21: 127-33.
11. 11 Wakefield AJ, Dillon AP, Rowles PM, et al. Pathogenesis of Crohn's disease. Multifocal gastrointestinal infarction. Lancet 1989; i: 1057-62.
12. 12 Murch SH, MacDonald TT, Walker Smith JA, et al. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 1993; 341: 711-4.
13. 13 Zovgorogniy LG, Mustyats AP. The use of anti-coagulant in combined therapy of non-specific colitis. Soviet Med (Moskva) 1982; 60: 74-80.
14. 14 Gaffney PR, Doyle CT, Gaffney A, et al. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995; 90: 220-3.
15. 15 Gaffney PR, O'Leary JJ, Doyle CT, et al. Response to heparin in patients with ulcerative colitis. Lancet 1991; 331: 238-9.
16. 16 Brazier F, Gouilleux Gruart V, Yzet T, et al. Effectiveness of heparin in the treatment of inflammatory bowel diseases: anticoagulant or immunomodulatory effect? Gut 1996; 39: A243(Abstract).
17. 17 Evans R, Wong VS, Morris AI, et al. Treatment of corticosteroid-resistant ulcerative colitis with heparin - a report of 16 cases. Aliment Pharmacol Ther 1997; 11: 1037-40.
18. 18 Folwaczny C, Wiebecke B, Loeschke K. Unfractionated heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999; 94: 1551-5.
19. 19 Harvey R, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1986; 8: 514.
20. 20 Baron JH, Connell AM, Lennard Jones JE. Variations between observers in describing mucosal appearances in proctocolitis. Br J Med 1964; 1: 89-92.
21. 21 Saverymuttu SH, Camilleri M, Rees H, et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in IBD. Gastroenterology 1986; 90: 1121-8.
22. 22 Korzenik JR, Robert ME, Bitton A, et al. A multicentre randomised controlled trials of heparin for the treatment of ulcerative colitis. Gastroenterology 1999; 116: A752(abstract).
23. 23 Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991; 60: 443-75.
24. 24 Rosenberg RD, Bayer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: J.B. Lippincott, 1994: 837-60.
25. 25 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
26. 26 Collins CE, Cahill MR, Newland AC, et al. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106: 840-5.
27. 27 Lake AM, Stauffer JQ, Steward MJ. Haemostatic alteration in IBD. Response to treatment. Am J Dig Dis 1978; 23: 897-902.
28. 28 De Jong E, Porte RJ, Knot EAR, et al. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa and faeces. Gut 1989; 30: 188-94.
29. 29 Boehme MWJ, Autschbach F, Zuna I, et al. Elevated serum levels and reduced immunohistochemical expression of thrombomodulin in active ulcerative colitis. Gastroenterology 1997; 113: 107-17.
30. 30 Leung L, Saigo K, Grant D. Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effect of histidine-rich-glycoprotein. Blood 1989; 73: 177-84.
31. 31 Castellot JJ, Wong K, Herman B, et al. Binding and internalisation of heparin by vascular smooth muscle cells. J Cellular Physiol 1985; 124: 13-20.
32. 32 Edelman ER, Nugent MA, Smith LT, et al. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest 1992; 89: 465-73.
33. 33 Attanasio M, Gori AM, Giusti B, et al. Cytokine gene expression in human LPS-and IFNγ-stimulated mononuclear cells is inhibited by heparin. Thromb Haemost 1998; 70: 959-62.
34. 34 White B, Ang YS, Mahmud N, Keeling PWN, Smith OP. Heparin and inflammatory bowel disease. Lancet 1999; 354: 1122-3.